Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 6Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia 3Urinary Bladder Neoplasms 2Sarcoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Glioblastoma 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neoplasms, Plasma Cell 1

Interventions

soluble LAG-3 protein, human 1cc-486 1avelumab 1Cytoreduction Surgical Procedures 1Cisplatin 1Carboplatin 1Azacitidine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Azacitidine × Genitourinary × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡